what are glp 1 agonist America's Poison Centers Hype Or Hope? Latest Research
Description
Prospective ultrasound studies show a higher prevalence of residual gastric content in GLP-1 RA users, particularly during dose escalation or when GI symptoms are present
Lifestyle modification and nutrition-based approaches are regarded as the cornerstone strategies for treating pediatric obesity
Recent signals underscore this shift: Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization [1] buoyed by global demand for obesity medications
Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62
